Early Uptake of Broad-Spectrum Antibiotic Prophylaxis in Pancreatoduodenectomy: Translating Trial Evidence into Practice

MedXY Editorial Team•Aug 21, 2026•General Surgery

Postoperative infections and pancreatic fistulas are significant complications after pancreatoduodenectomy, historically mitigated by cefoxitin prophylaxis.
A randomized trial demonstrated that piperacillin-tazobactam significantly reduces these postoperative complications compared to cefoxitin.
Analysis of over 27,000 patients from 220 hospitals showed an increase in broad-spectrum antibiotic use from 38.2% to 56.2% following dissemination of trial results.
Patients with preoperative biliary stents were more likely to receive broad-spectrum antibiotics, while racial disparities persist with Black/African American patients less likely to be prescribed these agents.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Postoperative infections and pancreatic fistulas are significant complications after pancreatoduodenectomy, historically mitigated by cefoxitin prophylaxis.
A randomized trial demonstrated that piperacillin-tazobactam significantly reduces these postoperative complications compared to cefoxitin.
Analysis of over 27,000 patients from 220 hospitals showed an increase in broad-spectrum antibiotic use from 38.2% to 56.2% following dissemination of trial results.
Patients with preoperative biliary stents were more likely to receive broad-spectrum antibiotics, while racial disparities persist with Black/African American patients less likely to be prescribed these agents.